

North Central Cancer Treatment Group

N0871: A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients with Measureable Disease with Cancer of Unknown Primary (CUP)

Status Change Notice – December 7, 2011

NOTICE OF STATUS CHANGE

Drug supply for RAD001 is now available. Therefore, this study will re-open to patient accrual effective Wednesday, December 7, 2011.

Please retain this notice with the protocol.